Norditropin Flexpro (Somatropin)

Somatropin, the active ingredient in Norditropin Flexpro, is a human growth hormone presented as a solution for subcutaneous use. It is used to treat growth hormone deficiency and related growth disorders in children and adults. GNH USA supplies Norditropin Flexpro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and transplant centres worldwide.

Norditropin Flexpro is a recombinant human growth hormone indicated for conditions involving impaired growth or metabolism.

Growth hormone deficiency: promotes linear growth and improves body composition in patients with confirmed deficiency. Turner syndrome: supports height gain and metabolic health in affected females. Prader‑Willi syndrome: helps increase stature and improve muscle tone. Chronic renal insufficiency: assists in growth and protein synthesis in children with renal disease. Small for gestational age (post‑natal): enhances growth velocity in children born small for gestational age.

Norditropin Flexpro may be associated with a range of adverse reactions.

Common Side Effects: - Injection site pain or erythema - Headache - Joint or muscle aches - Peripheral edema - Nausea or abdominal discomfort - Transient hyperglycemia

Serious or Rare Side Effects: - Intracranial hypertension - Slipped capital femoral epiphysis - Diabetes mellitus or worsening glucose control - Allergic reactions including anaphylaxis - Growth of pre‑existing malignancies - Cardiomyopathy or cardiac dysfunction

Before initiating therapy, clinicians should consider several safety measures.

Monitor IGF‑1 levels: adjust dose to maintain target range. Screen for malignancy: avoid use in active cancer patients. Assess glucose tolerance: monitor blood sugar in diabetics. Evaluate thyroid function: correct hypothyroidism before treatment. Caution in renal impairment: dose may need adjustment. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin can interact with several medications, requiring attention to avoid reduced efficacy or increased risk.

Major Interactions (Avoid): - Glucocorticoids: may blunt growth hormone effects. - Estrogen therapy: can increase IGF‑1 levels excessively. - Insulin: heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Oral hypoglycemic agents: may need dose adjustment. - Thyroid hormone replacement: monitor thyroid status. - Other hormonal therapies (e.g., testosterone): watch for synergistic effects.